Accelerate Diagnostics (NASDAQ:AXDX) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report issued on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 9.5 %

Shares of AXDX stock opened at $0.88 on Tuesday. The company’s fifty day moving average price is $1.15 and its 200-day moving average price is $1.43. The stock has a market cap of $21.97 million, a PE ratio of -0.31 and a beta of 0.55. Accelerate Diagnostics has a 12 month low of $0.73 and a 12 month high of $2.09.

Accelerate Diagnostics (NASDAQ:AXDX) last posted its quarterly earnings data on Thursday, March 20th. The medical research company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.13. The business had revenue of $2.82 million for the quarter, compared to the consensus estimate of $3.00 million. On average, sell-side analysts forecast that Accelerate Diagnostics will post -2.3 earnings per share for the current fiscal year.

Institutional Trading of Accelerate Diagnostics

Institutional investors have recently bought and sold shares of the company. Renaissance Technologies LLC raised its holdings in Accelerate Diagnostics by 160.6% in the fourth quarter. Renaissance Technologies LLC now owns 107,062 shares of the medical research company’s stock worth $128,000 after buying an additional 65,984 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Accelerate Diagnostics during the fourth quarter valued at approximately $27,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Accelerate Diagnostics during the third quarter valued at approximately $34,000. Finally, Geode Capital Management LLC raised its holdings in Accelerate Diagnostics by 6.9% in the 4th quarter. Geode Capital Management LLC now owns 135,732 shares of the medical research company’s stock worth $163,000 after acquiring an additional 8,777 shares during the last quarter. 17.14% of the stock is owned by hedge funds and other institutional investors.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.